Effekte pharmakologischer und psychotherapeutischer Interventionen auf Depressionen bei Kindern und Jugendlichen
Abstract
Zusammenfassung: Entgegen früheren Überzeugungen besteht heute Konsens und Evidenz dahingehend, dass Depressionen eine bedeutsame Problematik bei Jugendlichen darstellen. Aus diesem Grund stellt sich die Frage nach effektiven Therapieangeboten für depressive Kinder und Jugendliche. Deshalb werden in der vorliegenden Übersichtsarbeit 24 Originalstudien (Kriterium: kontrollierte, randomisierte Interventionsstudien) zu pharmakologischen, 11 Studien zu psychotherapeutischen Interventionen und zwei Studien zur Kombinationsbehandlung dargestellt. Für etwa die Hälfte der Behandlungmethoden (pharmakologische Methoden 3/8; psychotherapeutische Methoden: 2/5) liegen keine randomisierten Kontrollgruppenstudien vor. Weiterhin liegen nur für einige SSRIs (Fluoxetin, Citalopram, Sertralin) ausschließlich positive Daten bezüglich der Besserung depressiver Symptomatik vor. Weiterhin zeigen sich nur für Fluoxetin keine Hinweise, dass Suizidalität im Vergleich zu einer Placebokontrollgruppe steigt (Hammad et al., 2006; Whittington et al., 2004). Auch für KVT, IPT und Familientherapie liegen überwiegend positive Daten zur Effektivität vor. Weiterhin zeigen erste Ergebnisse, dass eine Kombinationsbehandlung (SSRI & KVT) Monotherapien gegenüber überlegen ist. Nach der Darstellung der bisherigen empirischen Daten werden Stärken und Kritikpunkte der bisherigen Therapieforschung zur Behandlung von Depression bei Kindern und Jugendlichen diskutiert.
Summary: Contrary to earlier assumptions, the current consensus is that depression constitutes an important issue in the mental health of children and adolescents. Thus, effective therapy options for depressive children and adolescents are needed. Randomized, controlled intervention studies are reviewed: 24 studies on pharmacological interventions, 11 studies on psychological interventions, and two on combination therapy. For approximately half of the intervention methods (pharmacotherapy: 3/8; psychotherapy: 2/5) no randomized, controlled studies carried out. Furthermore, only some SSRI (fluoxetin, citalopram and sertralin) yielded positive results with regard to depressive symptoms. Beyond these results, fluoxetin is the sole pharmacological treatment during which suicidality does not increase as compared to results for a placebo control group (Hammad et al., 2006; Whittington et al., 2004). Earlier studies of CBT, IPT, and family therapy reported predominantly positive effects. Nevertheless, initial results for combination therapies (SSRI & CBT) indicate an advantage of this therapy approach over mono-therapies. Empirical data are described, followed by a discussion of the strengths and limitations of the earlier studies.
Literatur
2002). Depression scale scores in 8-17-year-olds: effects of age and gendert. Journal of Child Psychology and Psychiatry, 43, 1052– 1063
(2006). Suicidal risk in antidepressant drug trials. Archives of General Psychiatry,, 63, 246– 248
(2000). Clinical outcome after sort-therm psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry, 57, 29– 36
(1996). Childhood and adolescent depression: A review of the past 10 years. Part I. Journal of the American Academy of Child Adolescent Psychiatry, 35, 1427– 1439
(1997). A clinical psychotherapy trial for adolescent depression coparing cognitive, family, and supportive therapy. Archives of General Psychiatry, 54, 877– 885
(1998). Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. Journal of the American Academy of Child Adolescent Psychiatry, 37, 906– 914
(1994). Increased rates of drug abuse and dependence after onset of mood or anxiety disorders in adolescence. Hospital Community Psychiatry, 45, 451– 455
(2005). A randomized effectiveness trail of brief cognitive-behavioral therapy for depressed adolescents receiving anti-depressant medication. Journal of the American Academy of Child Adolescent Psychiatry, 44, 888– 898
(2002). Group cognitive behavioral treatment for depressed adolescent offspring of depressed parents in a HMO. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 305– 313
(1999). Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 272– 279
(2002). Attachment-based family therapy for depressed adolescents. A treatment development study. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1190– 1196
(2003). Attachment-based Family Therapy for depressed adolescents: programmatic treatment development. Clinical Child and Family Psychology Review, 6, 107– 127
(2004). Efficacy and safety on venlafaxine ER in children and adolescents with major depression disorder. Poster presented at the 157th Annual Meeting of the American Psychiatric Association. New York: New York. May 1-6
(2002). Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. Journal of the American Academy of Child Adolescent Psychiatry, 41, 1205– 1215
(1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031– 1037
(2004). aroxetine treatment in children and adolescents with major depressive disorder. Poster presented at the 51th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC. October 19-24
(2002). Depression bei Kindern und Jugendlichen.. UTB, München
(2004a). Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and Pediatric Advisory Committee. www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1.htm. September 2004
(2004b). FDA statement on recommendations of the psychopharmacologic drugs and pediatric advisory committees. Available at: www.fda.gov/bbs/topics/news/2004/NEW01116.html. 16. September 2004
(2004). Depressionsbehandlung mit SSRI in der Kinder- und Jugendpsychiatrie. Nervenheilkunde, 23, 60– 64
(1990). Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a «fixed plasma level» design. Psychopharmacological Bulletin, 26, 85– 90
(2004). www.gsk.com/media/paroxetine.htm. August 2004
(2002). Depressive Kinder und Jugendliche. Göttingen Hogrefe.
(2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332– 339
(1990). Adult outcomes of childhood and adolescent depression, I: psychiatric status. Archives of General Psychiatry, 47, 465– 473
(2002). Die selektiven Serotonin-Wiederaufnahmehemmer und die neueren Antidepressivasubstanzen in der Kinder- und Jugendpsychiatrie. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 30, 173– 183
(2004). Leitlinien zur Diagnostik und Psychotherapie von depressiven Störungen im Kinder- und Jugendalter: Ein evidenzbasierter Diskussionsvorschlag. Kindheit und Entwicklung, 13, 64– 79
(2002a). Prävention, Behandlung und Rückfallprophylaxe depressiver Störungen im Jugendalter. Ein kognitiv-verhaltenstherapeutisches Gruppenprogramm nach Clarke & Lewinsohn. Tübingen: DGVT
(2002b). Mit depressiven Störungen im Jugendalter umgehen lernen. Ein Arbeitsbuch für Kursteilnehmer. Tübingen: DGVT
(The influence of child and adolescent psychiatric disorders on young adult personality disorder. . American Journal of Psychiatry, 156, 1529– 1535
1999,2001). Childhood depression and adult personality disorder. Alternative pathways of continuity. Archives of General Psychiatry, 58, 231– 236
(1984). Amitriptyline in children with major depressive disorder: a double-blind crossover pilot study. Journal of the American Academy of Child Adolescent Psychiatry, 23, 348– 351
(2001). Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Journal of the American Academy of Child Adolescent Psychiatry, 40, 762– 772
(1981). Clinical effects of amitriptyline in adolescent depression: a pilot study. Journal of the American Academy of Child Adolescent Psychiatry, 20, 636– 644
(1994). Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. Journal of the American Academy of Child Adolescent Psychiatry, 33, 686– 694
(1996). A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. Journal of the American Academy of Child Adolescent Psychiatry, 35, 1139– 1144
(1990). Cognitive-behavioral group treatment of depression in adolescents. Behavior Therapy, 21, 385– 401
(1997). Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacological Bulletin, 33, 149– 154
(2001). Familientherapie. In: G. Esser (Hrsg.). Lehrbuch der Klinischen Psychologie und Psychotherapie des Kindes- und Jugendalters (S. 488-512). Stuttgart: Thieme
(1999). Double-blind study of paroxetine in adolescents with unipolar major depression. American Academy of Child and Adolescent Psychiatry and Canadian Academy of Child Psychiatry Joint Annual Meeting, Chicago, Abstract
(1991). nterpersonal psychotherapy for adolescent depression: Description of modification and preliminary application. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 642– 651
(1999). Efficacy of interpersonal psychotherapy for depressed adolescents. Archives of General Psychiatry, 57, 573– 579
(1987). Depression in pre-pubertal children: dexamethasone nonsuppression predicts differential response to imipramine vs. placebo. Psychopharmacological Bulletin, 23, 128– 133
(1985). sychosocial functioning in prepubertal children with major depressive disorders: I. Interpersonal relationships during the depressive episode. Archives of General Psychiatry, 42, 500– 507
(1987). Imipramine in prepubertal major depressive disorders. Archives of General Psychiatry, 44, 81– 89
(June, 2005). Treating of adolescents with depression: findings from a multisite, randomized, controlled trial of CBT and Fluoxetine. 5th International Congress of Cognitive Psychotherapy, Goteburg: Sweden
(2001). Impact of comorbidity on a cognitive-behavioral group treatment for adolescent depression. Journal of the American Academy of Child Adolescent Psychiatry, 40, 795– 802
(2004). An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. Journal of the American Academy of Child Adolescent Psychiatry, 43, 660– 668
(1999). The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. Journal of Consulting and Clinical Psychology, 67, 734– 745
(2002). Efficacy and safety of nefazodone in adolescent with MDD. Poster presented at the 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA. May 18-23
(1999). Co-occurrence of mood and personality disorders. Depression and Anxiety, 10, 175– 182
(2003). Treatment for Adolescents with Depression Study (TADS): rationale, design, and methods. Journal of the American Academy of Child Adolescent Psychiatry, 42, 531– 542
(2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA, 292, 807– 820
(2002). Age, gender, race, socioeconomic status, and birth cohort differences on the Children’s Depression Inventory: a meta-analysis. Journal of Abnormal Psychology, 11, 578– 588
(1990). Psychological adjustment and experiences with peers during early adolescene: Reciprocal, incidental, or unidirectional relationships?. Journal of Abnormal Psychology, 18, 187– 198
(1998). Two-year outcome of children treated for depression. European Child and Adolescent Psychiatry, 7, 12– 18
(1996). A ranomised controlled out-patient trail of cognitive-behavioural treatment for children and adolescents with depression. 9-month follow-up. Journal of Affective Disorders, 40, 105– 116
(2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder - two randomized controlled trials. JAMA, 290, 1033– 1041
(2004a). Controlled trial of escitalopram in the treatment of pediatric depression. Poster presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC. October 19-24
(2004b). A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. American Journal of Psychiatry, 161, 1079– 1083
(1999). Depressed adolescents grown up. JAMA, 281, 1707– 1713
(2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet, 363, 1341– 1345
(1998). Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychological Medicine, 28, 109– 126
(1996). Controlled trial of a brief cognitive-behavioural intervention in adolescent patients with depressive disorders. Journal of Child Psychology and Psychiatry, 37, 737– 746
(